Curcumin as a protector for normal cells during bortezomib therapy

Hum Exp Toxicol. 2015 Jul;34(7):780-3. doi: 10.1177/0960327114555928. Epub 2014 Oct 28.

Abstract

This study evaluated the protective potential of curcumin on the possible side effects of bortezomib (Bt) therapy on normal cells in mice. The mice were segregated into three groups (n = 10) that included normal control, Bt-treated, and Bt + curcumin-treated groups. The Bt treatment resulted in significant decrease in the enzyme activity of erythrocyte δ-aminolevulinic acid dehydratase (ALAD). Also a significant decrease in the hemoglobin (Hb) was also noticed. On the other hand, curcumin co-treatment improvised enzyme activity of erythrocyte ALAD as well as Hb values. The study, therefore, concludes that curcumin co-treatment with Bt has a potential to take care of possible side effects of Bt therapy on normal cells.

Keywords: Drug toxicology; cancer biology; oxidative stress.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Agents / adverse effects*
  • Antineoplastic Agents / therapeutic use
  • Bortezomib / adverse effects*
  • Bortezomib / therapeutic use
  • Curcumin / pharmacology*
  • Erythrocytes / drug effects
  • Erythrocytes / metabolism
  • Hemoglobins / analysis
  • Male
  • Mice
  • Porphobilinogen Synthase / blood
  • Protective Agents / pharmacology*

Substances

  • Antineoplastic Agents
  • Hemoglobins
  • Protective Agents
  • Bortezomib
  • Porphobilinogen Synthase
  • Curcumin